Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Utilizing biomarkers in atrial fibrillation: the pros and cons — Wern Yew Ding (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Utilizing biomarkers in atrial fibrillation: the pros and cons
Shared by
Professor Gregory Lip
University of Liverpool
Utilizing biomarkers in atrial fibrillation: the pros and cons
Letter
2021
en
Authors
WD
Wern Yew Ding
GM
Garry McDowell
Professor Gregory Lip
University of Liverpool
Abstract
1 min read
TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2020
Understanding the global burden of atrial fibrillation and regional variations: we need improvement
Marco Vitolo
,
Professor Gregory Lip
Editorial Material
2021
Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation
Stanley Nattel
,
Professor Gregory Lip
,
David Filgueiras‐Rama
,
Dobromir Dobrev
Editorial Material
2021
Atrial fibrillation in the presence of chronic kidney disease: Toablate or not to ablate
Wern Yew Ding
,
Dhiraj Gupta
,
Christopher F. Wong
,
Professor Gregory Lip
Letter
2019
Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation
Professor Gregory Lip
,
Ahsan Ali Khan
,
Brian Olshansky
Article
2021
Atrial fibrillation and cognitive decline: it takes more than an irregular heart beat, to beat the brain
Dimitrios Sagris
,
Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.